Risk stratification and early detection biomarkers for precision HCC screening
Hepatology · 2023-07 · 78 (1) · 319-362
DOI: 10.1002/hep.32779 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hepatology, online erschienen am 11.10.2022. Verfasst von Yi-Te Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: California NanoSystems Institute , Crump Institute for Molecular Imaging , Department of Molecular and Medical Pharmacology , University of Californi…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 331 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a consequence of failed early detection. Professional societies recommend semi‐annual HCC screening in at‐risk patients with chronic liver disease to increase the likelihood of curative treatment receipt and improve survival. However, recent dynamic shift of HCC etiologies from viral to metabolic liver diseases has significantly increased the potential target population for the screening, whereas annual incidence rate has become substantially lower. Thus, with the contemporary HCC etiologies, the traditional screening approach might not be practical and cost‐effective. HCC screening consists of (i) definition of rational at‐risk population, and subsequent (ii) repeated application of early detection tests to the population at regular intervals. The suboptimal performance of the currently available HCC screening tests highlights an urgent need for new modalities and strategies to improve early HCC detection. In this review, we overview recent developments of clinical, molecular, and imaging‐based tools to address the current challenge, and discuss conceptual framework and approaches of their clinical translation and implementation. These encouraging progresses are expected to transform the current “one‐size‐fits‐all” HCC screening into individualized precision approaches to early HCC detection and ultimately improve the poor HCC prognosis in the foreseeable future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- California NanoSystems Institute , Crump Institute for Molecular Imaging , Department of Molecular and Medical Pharmacology , University of California , Los Angeles , California , USA.
- Liver Tumor Translational Research Program , Simmons Comprehensive Cancer Center , Division of Digestive and Liver Diseases , Department of Internal Medicine , University of Texas Southwestern Medical Center , Dallas ,…
- Karsh Division of Gastroenterology and Hepatology , Cedars-Sinai Medical Center , Los Angeles , California , USA.
- Comprehensive Transplant Center , Cedars-Sinai Medical Center , Los Angeles , California , USA.
- Samuel Oschin Comprehensive Cancer Institute , Cedars-Sinai Medical Center , Los Angeles , California , USA.
ORCID-Profile: Yi-Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida
Förderung
- NCI NIH HHS
- NIH HHS
- NIDDK NIH HHS
- European Research Council
Zitieren
APA
Lee, Y. T., Fujiwara, N., Yang, J. D., & Hoshida, Y. (2023). Risk stratification and early detection biomarkers for precision HCC screening. Hepatology, 78(1), 319-362. https://doi.org/10.1002/hep.32779
Vancouver
Lee YT, Fujiwara N, Yang JD, Hoshida Y. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology. 2023;78(1):319-362. doi:10.1002/hep.32779
BibTeX
@article{Lee2023,
author = {Lee, Yi-Te and Fujiwara, Naoto and Yang, Ju Dong and Hoshida, Yujin},
title = {Risk stratification and early detection biomarkers for precision HCC screening},
journal = {Hepatology},
year = {2023},
volume = {78},
number = {1},
pages = {319--362},
doi = {10.1002/hep.32779}
}
EUVIMED